HomeAI · summaries
Storia in 2 fonti
FDA expands Hympavzi use to all patients aged 6 years and older with hemophilia A, B
The FDA has expanded approval for marstacimab-hncq, which can now be given as routine prophylaxis for all individuals aged 6 years and older with hemophilia A or B, with or without inhibitors, Pfizer announced in a press release. Marstacimab-hncq (Hympavzi, Pfizer) is the first approved nonfactor, subcutaneous prophylaxis therapy for children with hemophilia B aged 6 to 11 years.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
FDA expands Hympavzi use to all patients aged 6 years and older with hemophilia A, B
The FDA has expanded approval for marstacimab-hncq, which can now be given as routine prophylaxis for all individuals aged 6 years and older with hemophilia A or B, with or…
- ·
fiercepharma.com
Pfizer scores FDA pediatric expansion for hemophilia treatment Hympavzi
The FDA has expanded the label for Pfizer’s subcutaneous hemop | The FDA has expanded the label for Pfizer’s Hympavzi, now including patients age 6 and older who have hemophilia A…